News Latest Sep 25, 2025 Theratechnologies Announces Completion of Acquisition by Future Pak Press Releases Year None20252024 May 02, 2025 Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV Apr 15, 2025 Theratechnologies Provides Update on Sale Process Apr 11, 2025 Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company Apr 09, 2025 Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements Apr 08, 2025 Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA Apr 03, 2025 Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update Mar 25, 2025 Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy Mar 12, 2025 Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV Mar 12, 2025 Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI Feb 26, 2025 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024 First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 11 - 20 of 61
May 02, 2025 Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
Apr 11, 2025 Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
Apr 09, 2025 Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
Apr 08, 2025 Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
Apr 03, 2025 Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
Mar 25, 2025 Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
Mar 12, 2025 Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
Mar 12, 2025 Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
Feb 26, 2025 Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
